3. The rights, safety, and well-being of the trial subjects are the most important considerations and shall prevail over interests of science and society .
See Section 2 of the Note for Guideline on Good Clinical Practice (CPMP/ICH/135/95) published by the European Agency for the Evaluation of Medicinal Products in July 2002.